AstraZeneca PLC
LSE:AZN
AstraZeneca PLC
Operating Income
AstraZeneca PLC
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
AstraZeneca PLC
LSE:AZN
|
Operating Income
$8.9B
|
CAGR 3-Years
27%
|
CAGR 5-Years
30%
|
CAGR 10-Years
9%
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Operating Income
£8.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
0%
|
CAGR 10-Years
2%
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Operating Income
$-67.6m
|
CAGR 3-Years
3%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
Indivior PLC
LSE:INDV
|
Operating Income
$270m
|
CAGR 3-Years
45%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Operating Income
$710m
|
CAGR 3-Years
11%
|
CAGR 5-Years
10%
|
CAGR 10-Years
7%
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Operating Income
£24.9m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
3%
|
See Also
What is AstraZeneca PLC's Operating Income?
Operating Income
8.9B
USD
Based on the financial report for Dec 31, 2023, AstraZeneca PLC's Operating Income amounts to 8.9B USD.
What is AstraZeneca PLC's Operating Income growth rate?
Operating Income CAGR 10Y
9%
Over the last year, the Operating Income growth was 1%. The average annual Operating Income growth rates for AstraZeneca PLC have been 27% over the past three years , 30% over the past five years , and 9% over the past ten years .